# Polycomb Silencing: Mechanisms, Regulation, and Biological Roles

## Introduction to Polycomb Silencing

Polycomb silencing is a conserved epigenetic mechanism by which cells stably repress specific sets of genes through the coordinated action of multiprotein complexes that modify chromatin. Unlike transient transcriptional repression mediated by sequence-specific repressors, Polycomb silencing establishes a heritable state of repression that persists through cell division, allowing daughter cells to "remember" which genes should remain off. This memory system is fundamental to development, where it maintains cell identity by locking in the appropriate gene expression programs.

### Historical context and discovery

The Polycomb story begins with classical Drosophila genetics. In the 1940s, Pamela Lewis described a mutation that caused homeotic transformations—extra sex combs on the second and third legs of male flies. Edward B. Lewis later characterized this locus in detail and named it *Polycomb* (Pc), noting that its loss caused transformations resembling those of *Ultrabithorax* mutations. The key insight came from the observation that Polycomb mutants ectopically expressed Hox genes in tissues where they should be silent, revealing that Polycomb normally functions as a repressor of Hox gene expression.

In the 1980s and 1990s, genetic screens in *Drosophila* identified additional members of the Polycomb group (PcG) and the counteracting trithorax group (trxG). Biochemical purification in the late 1990s and early 2000s, particularly from the laboratories of Renato Paro, Richard Jones, and Danny Reinberg, led to the identification of two principal complexes: Polycomb Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2). The discovery that PRC2 methylates histone H3 at lysine 27 (H3K27) and that PRC1 ubiquitinates histone H2A at lysine 119 (H2AK119) established the enzymatic basis of Polycomb silencing.

### Core concept: heritable gene repression

The defining feature of Polycomb silencing is its heritability. When a cell divides, the Polycomb-repressed state must be re-established on both daughter chromatids. This is achieved through a self-propagating loop: PRC2 writes H3K27me3 marks, which recruit PRC1; PRC1 then ubiquitinates H2AK119, which in turn stimulates further PRC2 activity. The modified histones are partitioned to daughter strands during DNA replication, and the chromatin environment they create serves as a template for re-establishing repression. This mechanism is a classic example of [Epigenetic Inheritance](/knowledge/molecular-biology/epigenetic-inheritance), where information is transmitted through cell divisions without changes to the underlying DNA sequence.

## The Core Polycomb Repressive Complexes

PRC1 and PRC2 are large, multi-subunit complexes that cooperate to silence target genes. Each complex contains a catalytic subunit, accessory proteins that regulate activity and targeting, and in some cases, subunits that recognize the histone modifications deposited by the other complex.

### PRC2: H3K27 methylation

PRC2 is the writer of H3K27 methylation. The core complex consists of four subunits: EZH2 (or its homolog EZH1), EED, SUZ12, and RbAp46/48 (RBBP7/RBBP4). EZH2 is the catalytic subunit, a SET-domain methyltransferase that transfers methyl groups from S-adenosylmethionine (SAM) to the ε-amino group of lysine 27 on histone H3. EZH2 can catalyze mono-, di-, and trimethylation (H3K27me1, H3K27me2, H3K27me3), with the trimethylated state being the hallmark of Polycomb repression.

EED is a WD40-repeat protein that recognizes the methylated tail of H3K27. This creates a positive feedback loop: when EED binds H3K27me3, it allosterically activates EZH2, promoting further methylation of neighboring nucleosomes. This mechanism allows the repressive mark to spread along chromatin. SUZ12 is a zinc-finger protein essential for complex stability and catalytic activity, while RbAp46/48 binds histone H4 and facilitates nucleosome engagement.

PRC2 exists in at least two variant complexes that differ in their accessory subunits. PRC2.1 contains Polycomb-like proteins (PCL1-3, also known as PHF19, MTF2, and PHF1), which bind to H3K36me3 and help recruit the complex to active gene bodies. PRC2.2 contains AEBP2 and JARID2, which enhance catalytic activity and facilitate recruitment to chromatin. The balance between these variants influences the targeting and processivity of H3K27 methylation.

### PRC1: H2AK119 ubiquitination

PRC1 is the writer of H2AK119 ubiquitination. The canonical PRC1 complex contains RING1A or RING1B (the catalytic E3 ligases), one of six PCGF proteins (PCGF1-6), and a combination of CBX, PHC, and RYBP/YAF2 subunits. RING1A/B catalyze the monoubiquitination of H2A at lysine 119, a modification that compacts chromatin and inhibits transcriptional elongation.

The composition of PRC1 determines its function. Canonical PRC1 (cPRC1) contains CBX proteins (CBX2, CBX4, CBX6, CBX7, or CBX8), which recognize H3K27me3 via their chromodomains, and PHC proteins (PHC1-3), which contain sterile alpha motif (SAM) domains that mediate oligomerization. This form of PRC1 is recruited to chromatin primarily through recognition of PRC2-deposited marks. Non-canonical PRC1 (ncPRC1) contains RYBP or YAF2 instead of CBX and PHC, and is recruited to chromatin through interactions with DNA-binding factors and long non-coding RNAs, independent of H3K27me3. ncPRC1 can deposit H2AK119ub1 at sites that lack pre-existing H3K27me3, and this ubiquitination can in turn recruit PRC2, establishing a hierarchy where PRC1 acts upstream of PRC2 at some loci.

## Molecular Mechanisms of Polycomb Silencing

Polycomb silencing is not a single event but a multi-step process involving the establishment of repression, its maintenance through cell division, and the physical compaction of chromatin. The two complexes cooperate through a series of positive feedback loops that reinforce the silenced state.

### Initiation vs. maintenance

Initiation of Polycomb silencing requires the recruitment of PRC1 and PRC2 to specific genomic loci. At many targets, ncPRC1 is recruited first through interactions with [transcription factors](/knowledge/molecular-biology/transcription-factor) or non-coding RNAs, and it deposits H2AK119ub1. This ubiquitination is recognized by PRC2, which is recruited and begins methylating H3K27. The H3K27me3 marks are then recognized by cPRC1, which binds and further compacts chromatin. This creates a self-reinforcing loop: H2AK119ub1 recruits PRC2, H3K27me3 recruits cPRC1, and cPRC1's catalytic activity adds more H2AK119ub1.

Maintenance of Polycomb silencing through DNA replication is a distinct challenge. During S phase, the replication fork disrupts nucleosomes, and the parental histones carrying H3K27me3 are distributed to the two daughter strands. The EED subunit of PRC2 binds these parental H3K27me3 marks and allosterically activates EZH2, which then methylates newly deposited H3 on the daughter strands. This "read-write" mechanism ensures that the repressive mark is re-established on both chromatids. Similarly, RING1B remains associated with chromatin during replication and can re-ubiquitinate H2A on newly assembled nucleosomes. The efficiency of this propagation is not perfect, and the system relies on the continued presence of Polycomb complexes at the locus to maintain repression over many cell divisions.

### Chromatin compaction and phase separation

Polycomb silencing involves more than just [histone modification](/knowledge/molecular-biology/histone-modification); it also involves the physical reorganization of chromatin. PRC1, particularly the canonical form containing PHC subunits, can compact chromatin in vitro. The SAM domains of PHC proteins oligomerize, bringing distant nucleosomes into close proximity. This compaction is thought to exclude RNA polymerase II and transcription factors from the silenced locus, creating a physical barrier to transcription.

Recent work has revealed that Polycomb complexes can undergo liquid-liquid phase separation, forming membraneless condensates that concentrate Polycomb components and their target loci. The intrinsically disordered regions of CBX2 and other Polycomb subunits drive this phase separation, and the resulting condensates are enriched for H3K27me3-modified chromatin. These Polycomb bodies are visible by immunofluorescence as discrete nuclear foci. Phase separation may explain how Polycomb silencing is maintained at high local concentrations of the complexes while allowing the rest of the genome to remain accessible. This process is intimately linked to [Chromatin Remodeling](/knowledge/molecular-biology/chromatin-remodeling), as the compaction and condensation of Polycomb domains require the coordinated action of histone modifiers and [chromatin remodelers](/knowledge/molecular-biology/chromatin-remodelers).

## Targeting Polycomb Complexes to Specific Genes

The specificity of Polycomb silencing—why some genes are repressed and others are not—depends on the mechanisms that recruit PRC1 and PRC2 to their target loci. Unlike bacterial repressors that bind specific DNA sequences, Polycomb complexes have limited intrinsic sequence specificity and rely on accessory factors for targeting.

### Polycomb response elements (PREs)

In *Drosophila*, Polycomb complexes are recruited to cis-regulatory DNA elements called Polycomb response elements (PREs). These are stretches of DNA, typically several hundred base pairs long, that contain clusters of binding sites for sequence-specific transcription factors. Key PRE-binding proteins include Pleiohomeotic (Pho) and its homolog Pho-like, which are the *Drosophila* homologs of the mammalian YY1 [transcription factor](/knowledge/molecular-biology/transcription-factor). Pho binds DNA directly and recruits PRC2 through physical interactions. Other PRE-binding factors include GAGA factor (GAF), which binds GA-rich sequences and helps establish a nucleosome-free region that facilitates complex loading, and Zeste, which binds PREs and interacts with both PRC1 and PRC2.

PREs are not defined by a single consensus sequence but rather by the combinatorial arrangement of binding sites for multiple factors. This degeneracy makes PREs difficult to predict computationally. In mammals, the situation is even more complex. While some PRE-like elements have been identified, including the D11.12 element in the *HoxD* cluster, mammalian Polycomb targeting appears to rely more heavily on CpG islands—GC-rich regions of DNA that are frequently found at gene promoters. PRC2 can bind CpG islands directly through its SUZ12 subunit, and the absence of DNA methylation at these islands is important for Polycomb recruitment.

### Role of long non-coding RNAs

Long non-coding RNAs (lncRNAs) play a significant role in targeting Polycomb complexes to specific loci. The best-studied example is *Xist*, a 17 kb lncRNA that is expressed from the inactive X chromosome in female mammals. *Xist* coats the chromosome from which it is transcribed and recruits PRC2 through direct RNA-protein interactions. The EZH2 subunit can bind RNA, and the *Xist* RNA contains specific repeat motifs that are recognized by PRC2. This recruitment leads to H3K27me3 deposition across the entire X chromosome, contributing to its silencing.

Other lncRNAs have been implicated in Polycomb targeting, including *HOTAIR*, which is transcribed from the *HOXC* locus and can recruit PRC2 to the *HOXD* locus in *trans*. However, the physiological relevance of *HOTAIR* in Polycomb targeting has been debated, and the extent to which lncRNAs generally direct Polycomb complexes to specific genes remains an active area of investigation. The relationship between Polycomb silencing and other forms of [RNA Silencing](/knowledge/molecular-biology/rna-silencing) is complex, as small RNAs can also influence Polycomb recruitment in some organisms, particularly in plants and fission yeast.

## Polycomb Silencing in Development and Cell Identity

Polycomb silencing is essential for development, where it maintains the repression of genes that must be turned off in specific cell types. The most well-characterized targets are the Hox genes, which specify the anterior-posterior body plan, but Polycomb also regulates genes involved in cell cycle control, differentiation, and pluripotency.

### Hox gene regulation

Hox genes are a family of homeodomain-containing transcription factors that are arranged in clusters in the genome. In mammals, there are four Hox clusters (*HoxA*, *HoxB*, *HoxC*, *HoxD*), each containing 9-11 genes. During development, Hox genes are expressed in a collinear fashion: genes at the 3' end of the cluster are expressed earlier and more anteriorly, while genes at the 5' end are expressed later and more posteriorly. Polycomb silencing is essential for maintaining the correct boundaries of Hox gene expression.

In *Drosophila*, Polycomb mutations cause the ectopic expression of Hox genes, leading to homeotic transformations such as the appearance of legs on the head. In mammals, loss of PRC2 components leads to posterior transformations of the axial skeleton, reflecting the anterior expansion of Hox gene expression. The *Hox* clusters are enriched in H3K27me3 in cells where the genes are silent, and the boundaries of H3K27me3 domains correspond to the boundaries of gene expression. During differentiation, Polycomb marks are removed from genes that need to be activated, and this removal is mediated by the trithorax group proteins, which deposit the activating H3K4me3 mark and by the H3K27 demethylases UTX and JMJD3.

### X-chromosome inactivation

X-chromosome inactivation is a form of dosage compensation in female mammals, where one of the two X chromosomes is silenced to equalize gene expression between males (XY) and females (XX). This process is initiated by the *Xist* lncRNA, which is expressed from the future inactive X chromosome and spreads along it in *cis*. *Xist* recruits Polycomb complexes, leading to the deposition of H3K27me3 and H2AK119ub1 across the entire chromosome. The inactive X chromosome becomes a facultative heterochromatin structure, visible as the Barr body.

Polycomb silencing is critical for the initiation and maintenance of X inactivation. PRC2 is recruited to the inactive X chromosome early in the process, and H3K27me3 is one of the earliest marks of the inactive state. The Polycomb marks are maintained throughout the lifetime of the organism, ensuring that the inactive X remains silent. Interestingly, the inactive X chromosome also acquires DNA methylation at CpG islands, which provides a more permanent layer of repression. This illustrates how Polycomb silencing can cooperate with other repressive mechanisms to establish stable gene silencing. The inactive X chromosome is also subject to [Genomic Imprinting](/knowledge/molecular-biology/genomic-imprinting) in some contexts, as the choice of which X chromosome to inactivate can be influenced by parental origin in certain tissues.

## Polycomb Silencing in Disease

Given the central role of Polycomb silencing in development and cell identity, it is not surprising that its dysregulation contributes to a wide range of human diseases, most notably cancer. Both loss-of-function and gain-of-function mutations in Polycomb components have been identified in various malignancies.

### Oncogenic mutations in PRC2

PRC2 components are frequently mutated in cancer, but the pattern of mutations is complex and context-dependent. In some cancers, PRC2 components act as tumor suppressors. For example, in T-cell acute lymphoblastic leukemia (T-ALL), inactivating mutations in EZH2, SUZ12, and EED are common, and loss of PRC2 function leads to aberrant activation of genes that promote proliferation. Similarly, in malignant rhabdoid tumors, loss of the SWI/SNF [chromatin remodeling](/knowledge/molecular-biology/chromatin-remodeling) complex component SNF5 leads to PRC2-dependent repression of [tumor suppressor genes](/knowledge/molecular-biology/tumor-suppressor-gene), and PRC2 inhibitors can reactivate these genes and suppress tumor growth.

In other cancers, PRC2 components act as oncogenes. The most well-characterized example is the gain-of-function mutation Y641 in EZH2, which is found in diffuse large B-cell lymphoma and follicular lymphoma. This mutation alters the substrate specificity of EZH2, increasing its ability to catalyze the trimethylation of H3K27 while reducing its activity for mono- and dimethylation. The net effect is a global increase in H3K27me3 levels, leading to aberrant repression of tumor suppressor genes. These mutations are heterozygous, and the mutant allele acts in a dominant manner, cooperating with the wild-type allele to drive hypermethylation.

### Polycomb as a therapeutic target

The dependence of some cancers on PRC2 activity has made Polycomb complexes attractive therapeutic targets. The first PRC2 inhibitor to enter clinical trials was tazemetostat (EPZ-6438), a selective inhibitor of EZH2 that competes with SAM for binding to the enzyme's active site. Tazemetostat has shown efficacy in patients with epithelioid sarcoma and follicular lymphoma, particularly those with EZH2 mutations. Other EZH2 inhibitors, including GSK126 and CPI-1205, have also been developed and are in various stages of clinical testing.

PRC1 is also being explored as a therapeutic target. Inhibitors of RING1B, such as RB-3, have been developed and shown to reactivate Polycomb-silenced genes in cancer cells. However, the therapeutic window for PRC1 inhibitors is narrower than for PRC2 inhibitors, as PRC1 is essential for normal development and its systemic inhibition may cause significant toxicity. Combination strategies, where Polycomb inhibitors are used together with other epigenetic drugs or conventional chemotherapy, are also being explored. The success of these approaches depends on a detailed understanding of which Polycomb targets are critical for tumor survival and how resistance to Polycomb inhibitors develops.

## Methods to Study Polycomb Silencing

Studying Polycomb silencing requires a combination of approaches that assess the localization of Polycomb complexes and their histone modifications, the transcriptional status of target genes, and the functional consequences of perturbing Polycomb activity.

### ChIP-seq for histone marks

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is the standard method for mapping the genomic localization of Polycomb complexes and their associated histone modifications. In a typical ChIP experiment, cells are crosslinked with 1% formaldehyde for 10 minutes at room temperature to covalently link proteins to DNA. The chromatin is then sheared by sonication to fragments of 200-600 base pairs. Antibodies specific to the protein of interest—for example, anti-H3K27me3 or anti-EZH2—are used to immunoprecipitate the protein-DNA complexes. After reversing the crosslinks and purifying the DNA, the enriched fragments are sequenced and mapped to the genome.

ChIP-seq for H3K27me3 typically reveals broad domains of enrichment, often spanning tens of kilobases, that correspond to Polycomb-repressed loci. In contrast, ChIP-seq for PRC2 components such as EZH2 or SUZ12 often shows narrower peaks at promoters and CpG islands. The quality of ChIP-seq data depends critically on antibody specificity, and it is essential to validate antibodies using knockout cells or peptide competition assays. A related technique, CUT&RUN (Cleavage Under Targets and Release Using Nuclease), uses a protein A-micrococcal nuclease fusion to cleave chromatin at antibody-bound sites, requiring fewer cells and producing lower background than traditional ChIP.

### RNA-seq for gene expression

RNA sequencing (RNA-seq) is used to assess the transcriptional consequences of Polycomb perturbation. In a typical experiment, total RNA is isolated, ribosomal RNA is depleted, and the remaining RNA is converted to cDNA and sequenced. The number of reads mapping to each gene provides a quantitative measure of its expression level. Comparing RNA-seq data from cells with and without Polycomb function identifies genes that are derepressed upon Polycomb loss.

RNA-seq is often combined with ChIP-seq to correlate changes in gene expression with changes in [histone modification](/knowledge/molecular-biology/histone-modification) status. For example, genes that gain H3K27me3 upon overexpression of EZH2 and also show decreased expression are likely direct targets of Polycomb repression. However, the relationship between H3K27me3 levels and gene expression is not always linear, and some genes can be marked by H3K27me3 without being fully silenced. Therefore, RNA-seq data must be interpreted in the context of other measurements, such as the occupancy of RNA polymerase II and the levels of nascent transcription.

### Genetic and biochemical assays

Genetic approaches are essential for establishing the functional requirements of Polycomb components. In *Drosophila*, classical genetic screens have identified PcG genes based on their homeotic phenotypes. In mammals, conditional knockout mice have been generated for most Polycomb components, allowing the study of their function in specific tissues and developmental stages. For example, conditional deletion of EZH2 in the hematopoietic system has revealed its role in maintaining hematopoietic stem cell identity.

Biochemical assays are used to study the enzymatic activities of Polycomb complexes. Histone methyltransferase assays measure the incorporation of radiolabeled methyl groups from [³H]-SAM into histone substrates. In a typical assay, recombinant PRC2 is incubated with histone H3 or nucleosomes in a buffer containing 50 mM Tris-HCl (pH 8.0), 5 mM MgCl₂, 1 mM DTT, and 1 µM [³H]-SAM for 30 minutes at 30°C. The reaction is stopped by spotting onto P81 phosphocellulose paper, which binds histones, and the incorporated radioactivity is measured by scintillation counting. Similar assays are used for PRC1 ubiquitination, where RING1B is incubated with ubiquitin, E1 and E2 enzymes, and nucleosomal substrates, and the ubiquitinated H2A is detected by western blotting with an anti-H2AK119ub1 antibody.

## Common Pitfalls and Misconceptions

Polycomb silencing is a complex process, and several misconceptions are common among students and even experienced researchers. Understanding these pitfalls is essential for correctly interpreting experimental data and designing informative experiments.

### Polycomb silencing is not permanent

A common misconception is that Polycomb silencing is an irreversible state, akin to the permanent inactivation of a gene by mutation. In reality, Polycomb silencing is dynamically regulated and can be reversed. During development, Polycomb target genes are frequently activated in specific cell types, and this activation requires the removal of Polycomb marks. The H3K27 demethylases UTX and JMJD3 can remove methyl groups from H3K27me3, and the trithorax group protein ASH1L can counteract Polycomb by depositing activating marks. Additionally, the Polycomb complexes themselves can be displaced from chromatin by transcriptional activators and by the process of transcription itself.

The reversibility of Polycomb silencing is also evident in experimental settings. Treatment of cells with EZH2 inhibitors leads to the loss of H3K27me3 and the reactivation of Polycomb target genes within days. Similarly, overexpression of transcription factors that bind Polycomb target genes can overcome repression. This reversibility is a key feature that distinguishes Polycomb silencing from the more permanent silencing mediated by DNA methylation at imprinted loci, although the two mechanisms can cooperate.

### Distinction from DNA methylation

Polycomb silencing and DNA methylation are both [epigenetic mechanisms](/knowledge/molecular-biology/epigenetic-mechanisms) that repress gene expression, but they are fundamentally different. DNA methylation involves the covalent addition of a methyl group to cytosine residues in CpG dinucleotides, catalyzed by DNA methyltransferases (DNMTs). DNA methylation is generally more stable than Polycomb silencing and is harder to reverse. In contrast, Polycomb silencing involves histone modifications—methylation of H3K27 and ubiquitination of H2AK119—which are more dynamic and can be actively removed by demethylases and deubiquitinases.

The relationship between Polycomb silencing and DNA methylation is complex. In some contexts, Polycomb and DNA methylation are mutually exclusive: CpG islands that are marked by H3K27me3 are typically unmethylated, and vice versa. In other contexts, the two mechanisms cooperate. For example, during X-chromosome inactivation, Polycomb marks are established early and are followed by DNA methylation at CpG islands, which provides a more permanent layer of repression. In cancer, the relationship can be disrupted, with aberrant DNA methylation at CpG islands that are normally Polycomb targets, leading to more stable silencing. It is important to remember that Polycomb silencing is a form of [Gene Silencing](/knowledge/molecular-biology/gene-silencing) that is mechanistically distinct from the classical bacterial models of repression such as the [Lac Operon](/knowledge/molecular-biology/lac-operon) and [Trp Operon](/knowledge/molecular-biology/trp-operon), which involve sequence-specific repressors and do not involve chromatin modifications.

## Summary and Key Takeaways

Polycomb silencing is a fundamental epigenetic mechanism that maintains heritable gene repression during development and throughout the life of an organism. The two core complexes, PRC1 and PRC2, cooperate through a series of positive feedback loops to establish and maintain repressive chromatin domains. The specificity of Polycomb targeting is achieved through DNA elements, transcription factors, and non-coding RNAs, and the system is dynamically regulated to allow gene activation during differentiation. Dysregulation of Polycomb silencing contributes to cancer and other diseases, making Polycomb complexes important therapeutic targets.

## Frequently Asked Questions

### What is polycomb silencing?

Polycomb silencing is an epigenetic mechanism that stably represses specific genes through the action of Polycomb Repressive Complexes 1 and 2 (PRC1 and PRC2). These complexes deposit histone modifications—H3K27me3 by PRC2 and H2AK119ub1 by PRC1—that compact chromatin and block transcription. The repressed state is heritable, meaning it is maintained through cell division, allowing cells to remember which genes should remain off.

### How does polycomb silencing work?

Polycomb silencing works through a coordinated series of events. PRC2 methylates histone H3 at lysine 27, and PRC1 ubiquitinates histone H2A at lysine 119. These modifications recruit additional Polycomb complexes and compact chromatin, excluding RNA polymerase and transcription factors. The system is self-reinforcing: H2AK119ub1 recruits PRC2, H3K27me3 recruits PRC1, and the marks are propagated to daughter cells during DNA replication.

### What is the difference between PRC1 and PRC2?

PRC1 and PRC2 are distinct complexes with different catalytic activities. PRC2 contains EZH2, which methylates H3K27, and its core subunits EED, SUZ12, and RbAp46/48. PRC1 contains RING1A/B, which ubiquitinates H2AK119, and various accessory subunits. PRC2 writes the H3K27me3 mark, while PRC1 writes the H2AK119ub1 mark. The two complexes cooperate, with each recognizing the marks deposited by the other.

### Is polycomb silencing reversible?

Yes, Polycomb silencing is reversible. H3K27me3 can be removed by the demethylases UTX and JMJD3, and H2AK119ub1 can be removed by deubiquitinases such as BAP1. During development, Polycomb target genes are activated in specific cell types through the removal of Polycomb marks and the deposition of activating marks. Pharmacological inhibitors of EZH2 can also reverse Polycomb silencing.

### What are polycomb response elements (PREs)?

Polycomb response elements (PREs) are cis-regulatory DNA sequences that recruit Polycomb complexes to target genes. They were first identified in *Drosophila* and contain clusters of binding sites for sequence-specific transcription factors such as Pleiohomeotic (Pho) and GAGA factor. In mammals, PREs are less well-defined, and Polycomb targeting relies more on CpG islands and long non-coding RNAs.

### How is polycomb silencing studied?

Polycomb silencing is studied using a combination of approaches. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) maps the genomic localization of Polycomb complexes and histone modifications. RNA sequencing (RNA-seq) measures the transcriptional consequences of Polycomb perturbation. Genetic experiments in model organisms establish functional requirements, and biochemical assays measure the enzymatic activities of PRC1 and PRC2.

### What happens when polycomb silencing goes wrong?

Dysregulation of Polycomb silencing contributes to many diseases, particularly cancer. Loss-of-function mutations in PRC2 components can lead to aberrant gene activation and tumor development, as seen in T-cell acute lymphoblastic leukemia. Gain-of-function mutations in EZH2, such as Y641, cause hypermethylation of H3K27 and repression of tumor suppressor genes, as seen in diffuse large B-cell lymphoma. Polycomb dysregulation is also implicated in developmental disorders and neurological diseases.

## Key Takeaways

- Polycomb silencing is a heritable epigenetic mechanism that represses specific genes through the coordinated action of PRC1 and PRC2.
- PRC2 methylates H3K27, and PRC1 ubiquitinates H2AK119, creating self-reinforcing repressive chromatin domains.
- Polycomb complexes are recruited to target genes through DNA elements (PREs), transcription factors, and long non-coding RNAs such as *Xist*.
- Polycomb silencing is essential for Hox gene regulation, X-chromosome inactivation, and the maintenance of cell identity during development.
- Polycomb silencing is reversible, and its dynamic regulation is critical for proper gene activation during differentiation.
- Dysregulation of Polycomb components, particularly EZH2, contributes to cancer, making Polycomb complexes important therapeutic targets.
- Polycomb silencing is studied using ChIP-seq, RNA-seq, genetic approaches, and biochemical assays, each providing complementary information about the mechanism.

## Further Reading

- Pirrotta V. *Polycomb silencing mechanisms and genomic programming*. Ernst Schering Research Foundation workshop. 2006. [PubMed 16568951](https://doi.org/10.1007/3-540-37633-x_6)
- Cheutin T, Cavalli G. *Polycomb silencing: from linear chromatin domains to 3D chromosome folding*. Current opinion in genetics & development. 2014. [PubMed 24434548](https://doi.org/10.1016/j.gde.2013.11.016)
- Schwartz YB, Pirrotta V. *Polycomb silencing mechanisms and the management of genomic programmes*. Nature reviews. Genetics. 2007. [PubMed 17173055](https://doi.org/10.1038/nrg1981)
- Pirrotta V. *Polycomb silencing and the maintenance of stable chromatin states*. Results and problems in cell differentiation. 1999. [PubMed 10339748](https://doi.org/10.1007/978-3-540-69111-2_10)
- Xu M et al. *A repressive H3K36me2 reader mediates Polycomb silencing*. Nature communications. 2024. [PubMed 39179589](https://doi.org/10.1038/s41467-024-51789-6)
- Hunt G, Boija A, Mannervik M. *p300/CBP sustains Polycomb silencing by non-enzymatic functions*. Molecular cell. 2022. [PubMed 36206738](https://doi.org/10.1016/j.molcel.2022.09.005)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)